Wednesday, February 10, 2010, 1:51PM AEST - The Australian Stockmarket closes in 2 hours and 14 minutes.
To create a watchlist or portfolio of shares, Register

Amylin Pharmaceuticals, Inc. (AMLN)

8:00AM AEST: 17.43 USD  Up 0.10 (0.58%)  
 MORE ON AMLN 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Amylin Pharmaceuticals, Inc. (NasdaqNM:AMLN) Delayed quote dataEdit
Last Trade:17.43 USD
Trade Time: 8:00AM AEST
Change:Up 0.10 (0.58%)
Prev Close:17.33
Open:17.51
Bid:17.02 x 100
Ask:17.49 x 100
1y Target Est:15.33
Day's Range:17.29 - 17.79
52wk Range:7.89 - 19.99
Volume:1,818,418
Avg Vol (3m):3,193,350
Market Cap:2.47B
P/E (ttm):N/A
EPS (ttm):-1.68
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add AMLN to Portfolio   Download Data

 HEADLINES 
Biotech ETFs Immune To Broad Selling
Investor's Business Daily (Tue 9:34AM)
Alkermes Retains Neutral Rec
Zacks.com (Tue 7:07AM)
AMYLIN PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Sat, Feb 6)
Alkermes Testing its Version of Popular Schizophrenia Drug
at TheStreet.com (Fri, Feb 5)
Alkermes Testing Schizophrenia Drug
at TheStreet.com (Fri, Feb 5)
Novo Nordisk Has High Hopes for Diabetes Blockbuster
at Seeking Alpha (Wed, Feb 3)
The Shaky State Of California Biopharma
at CNBC (Wed, Feb 3)
Eli Lilly and the Depression-Diabetes Circle
at Minyanville.com (Wed, Feb 3)
UPDATE - Novo Nordisk ups outlook, Q4 EBIT beats consensus
at Reuters (Wed, Feb 3)
2-Star Stocks Poised to Plunge: MannKind?
at Motley Fool (Wed, Feb 3)
Weekly Street Sentiment: Mostly Cloudy with a Chance of Sunshine
at Seeking Alpha (Wed, Feb 3)
Monday Options Recap
at Seeking Alpha (Tue, Feb 2)
PREVIEW-Novo Nordisk Q4 seen down but 2010 rosier
at Reuters (Tue, Feb 2)
Novo Nordisk Awaits China Approval of Diabetes Treatment
at Seeking Alpha (Mon, Feb 1)
[$$] 13D Filings
at Barrons.com (Sat, Jan 30)
More Headlines for AMLN...

 ANALYST 
EPS Est (next year) (Dec-09) :-1.26
EPS Est (in 2 years) (Dec-10) :-0.68
Avg Rec (current)*:2.9
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Amylin Pharmaceuticals, Inc., a biopharmaceutical company, focuses on improving the lives of people with diabetes, obesity, and other diseases through the discovery, development, and commercialization of innovative medicines.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices